End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.96 CNY | -0.99% | -2.29% | -24.40% |
Mar. 15 | Hepalink Pharmaceutical Gets Lifeline from Controlling Shareholder | MT |
Feb. 29 | Nomura Adjusts Aier Eye Hospital Group’s Price Target to 22.14 Yuan From 25.03 Yuan, Keeps at Buy. | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 31.68 and 25.23 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.40% | 15.55B | B+ | ||
+1.80% | 12.05B | B | ||
+2.82% | 11.5B | B+ | ||
+10.15% | 10.69B | B+ | ||
+24.10% | 8.26B | B | ||
-0.40% | 7.79B | A- | ||
+22.90% | 7.31B | D | ||
+5.73% | 6.75B | B- | ||
+50.39% | 4.51B | - | ||
-3.73% | 4.33B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300015 Stock
- Ratings Aier Eye Hospital Group Co., Ltd.